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Etoxadrol-mera-isothiocyanate (2S,4S,692-ethyl-2-(3-isothiocyanatophenyl)-2-pi~ridyl)1,3-dioxolane, 4n) has been 
synthesized and characterized as an irreversible ligand for the phencyclidine (PCP)-binding site. It is the first chiral elec- 
trophilic affinity ligand for this site to have been described. This affinity ligand is based upon etoxadrol, a 1,3-dioxolane 
known to have PCP-like effects in vivo and in vitro. Etoxadrol-meta-isothiocyanate was found to be four-five times more 
potent in vitro than metaphit (1-[1-(3-isothiocyanatophenyl)cyclohexyl]pi~~dine), the only previously known electro- 
philic affinity ligand for the PCP-binding site. The binding was shown to be highly enantioselective for etoxadrol-meta- 
isothiocyanate (4a). The 2R,4R,6R-enantiomer of 4a was essentially inactive. The ability of the 2S,4$69enantiomer (4a) 
to interact with the benzodiazepine, muscarinic, and mu opioid receptor systems was also examined, and it was found 
not to interact with these receptor systems. It seems likely that 4a will prove to be a valuable tool in the study of structure 
and function of the PCP-binding site. 
Phencyclidine-binding site; Etoxadrol-meta-isothiocyanate; Etoxadrol; 1,3-Dioxolane; Electrophilic affinity ligand; 
Enantioselective irreversible ligand 
1. INTRODUCTION 
The acylating agent metaphit (1-[1-(3-isothio- 
cyanatophenyl)cyclohexyl]piperidine, 1, fig. 1) [l] 
has been utilized with great success as a tool for the 
characterization of the PCP-binding site. The en- 
couraging results obtained from the many studies 
[2-l l] involving this agent have initiated efforts in 
our laboratory toward the synthesis and 
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biochemical characterization of more potent af- 
finity ligands related to structurally diverse PCP 
agonists. The dissociative anesthetics dexoxadrol 
(4S,6S-2,2-diphenyl-4-(2-piperidyl)-1,3-dioxolane, 
2) and etoxadrol (2S,4S,6S-2-ethyl-2-phenyl-4-(2- 
piperidyl)-1,3-dioxolane, 3) have been shown to 
competitively inhibit the binding of [3H]TCP to 
stereoselective, saturable-binding sites in rat brain 
[12]. The availability of an electrophilic affinity 
ligand structurally related to these dioxolanes 
could serve to complement metaphit in further 
studies of this binding site. This goal has been 
made more pertinent by recent studies which in- 
dicate that some heterogeneity may exist between 
the binding sites of these two classes of compounds 
[13]. We now report the synthesis and 
characterization of an electrophilic affinity ligand, 
2S,4S,6S-2-ethyl-2-(3-isothiocyanatopheny1)-4-(2- 
piperidyl)- 1,3-dioxolane (etoxadrol-meta-isothio- 
cyanate, 4a), which is stereochemically and struc- 
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turally related to etoxadrol, shows good affinity 
for the [3H]TCP-binding site in rat brain homo- 
genates, and which is enantioselective. The enan- 
tiomeric 2R,4R,6R-etoxadrol-meta-isothiocyanate 
does not acylate nor have affinity for the PCP- 
binding site, except at very high concentrations. 
chromatography (88% CHCl, : 11% MeOH : 1% NI-bOH). The 
diastereometric configuration at the C-2 carbon of 6a and 6b 
was assigned by comparison of their NMR spectra with the 
NMR spectra of etoxadrol and epietoxadrol [16]. Exact mass 
calculated for CZ~H~ONZO~ was 406.2104 (found, 406.2111). 
2.4. 2-(3-Aminophenyl)-2-ethyl-4-(I_P-butoxycarbonyl)-2- 
piperidyl)-l,3-dioxolanes (la,b) 
2. MATERIALS AND METHODS 
2.1. Chemical synthesis 
The synthesis of 2S,4S,6Setoxadrol-meta-isothiocyanate (4a) 
is shown in fig. 1. The 2S,392-piperidyl-1,2-ethanediol was ob- 
tained by the hydrolysis of dexoxadrol as previously described 
[14]. Synthesis of the (+)-2R,4R,6R-enantiomer was carried 
out in a similar fashion using 2R,3R-2-piperidyl-l,2-ethanediol 
[14] as the starting material. Spectra from nuclear magnetic 
resonance (Varian XL300 spectrometer), infrared (Beckmann 
3001 instrument), and chemical ionization (Cl) mass spectra 
(Finnegan Mat-311 spectrometer) were in accorq with the 
assigned structures. Gas chromatographic (CC) analysis utilized 
a Hewlett-Packard 588OA instrument with a carbowax capillary 
column and flame ionization detector. Melting points were ob- 
tained using a Thomas-Hoover Unimelt apparatus and are un- 
corrected. Thin layer chromatography (TLC) was performed on 
Analtech silica gel GF plates eluted with a mixture of 
chloroform/methanol/cone. ammonium hydroxide (90: 9 : 1) 
and visualized by iodine staining. All new compounds gave 
combustion analyses for carbon, hydrogen and nitrogen within 
+ 0.4% of the calculated value and were performed by Atlantic 
Microlabs, Atlanta, GA. 
A solution of 6a and 6b (980 mg) in methanol (20 ml) was 
hydrogenated over 60 mg of 10% Pd on carbon at 3 at- 
mospheres pressure for 5 h. After filtration of the catalyst, the 
amine products (7a,b) were obtained (99%) by concentration of 
the reaction mixture. Analysis by CC indicated no change in the 
ratio of isomers during the hydrogenation. Exact mass 
calculated for C~~H32N204 was 376.2362 (found, 376.2384). 
2.5. 2-(3-Isothiocyanatophenyl)-2-ethyl-4-(I-t-butoxycarbo- 
nyl)-2-piperidyl)-I,3-dioxolanes (Ea,b) 
Thiophosgene in pentene-stabilized chloroform (0.71 ml of a 
2.78 N solution) was added to a two-phase mixture of a solution 
of 7a,b (739 mg, 1.96 mmol) in 4 ml of pentene-stabilized 
chloroform and a saturated sodium bicarbonate solution 
(4 ml). After 20 min the organic layer was removed by pipette 
and dried by passage through a short packed column of 
anhydrous MgS04. Concentration of the resulting filtrate gave 
a mixture of isomeric isothiocyanates (8a,b), m.p. 63-66”C, 
which could be separated by column chromatography. 
However, attempts to deprotect the individual isothiocyanate 
diastereomers 8a and 8b resulted in the scrambling of the 
stereochemistry at C-2. Thus, the isomeric mixture 8a,b was 
subjected to the deprotection conditions and the desired 
product 4a was separated from its epimer 4b by recrystallization 
(see below). 
2.2. 2-(3-Nilrophenyl)-2-ethyl-4-(2-piperidyl)-l,3-dioxolanes 
Pa,b) 2.6. ZS,4S,6S-2-(3-Isoihiocyanatophenyl)-2-ethyl-4-(2- 
A solution of 2S,3S-2-piperidyl-1,2-ethanediol (1.19 g, 
8.21 mmol) and p-toluenesulfonic acid (1.71 g, 9.03 mmol) in 
5 ml of acetonitrile was evaporated to dryness. The residue was 
dissolved in nitromethane and extracted (Soxhlet extractor con- 
taining neutral active alumina (2 g) in the stock; the mixture 
was refluxed; and m-nitropropiophenone dimethyl acetal 
(2.03 g, 9.0 mmol) [15] was then added in one portion). After 
1 h reaction time, the cooled (25°C) reaction mixture was 
separated by extraction with a mixture of ether (40 ml) and 
1.0 N sodium hydroxide solution (20 ml). The crude material 
from the organic layer, after drying (MgSOd) and concentra- 
tion, was purified by silica gel chromatography (9Oqo 
CHCls :9% MeOH: 1% NHdOH) to give 2.05 g (81%) of a 
mixture of the diastereometric ketals Sa,b. TLC Rr 0.54 and 
0.50, m.p. 176-178°C (HCI salt). 
piperidyl)-1,3-dioxolane (4a) 
2.3. 2-(3-Ni@ophenyl)-2-ethyl-4-(I-(t-butoxy carbonyl)-2- 
piperidyl)-I,3-dioxolanes (6a,b) 
To a solution of Sa,b (1.1 g, 3.6 mmol) in pentene-stabilized 
chloroform (15 ml) was added di-t-butyl dicarbonate (0.942 g, 
1.2 equivalents). A second layer of 2.90 N sodium bicarbonate 
was added and the solution stirred overnight. The chloroform 
layer was removed, dried (MgSOa), and concentrated to give 
1.42 g (97%) of a mixture of isomers. CC of the mixture in- 
dicated a 65 : 35 ratio of 2.9: 2R isomers, 6a and 6b, respectively. 
A portion of the diastereometric mixture was separated by flash 
The t-BOC protected isothiocyanate 8a,b (625 mg, 
1.5 mmol) was dissolved in dry diethyl ether (10 ml) in a small 
pressure bottle. A dry solution of diethyl ether saturated with 
HCl gas (3 ml) was added and the bottle sealed and brought to 
40°C using a warm sand bath. The deprotected product 4a 
separated as its hydrochloride salt in about 20 min. The solvent 
was decanted and the residual semicrystalline product was rin- 
sed twice with dry ether. The salt (a 65 : 35 mixture of 4a and 
its C-2 epimer 4b) was dissolved in hot ethyl acetate and crystal- 
lized by careful trituration with isooctane to give a 92: 8 mixture 
of 4a and 4b. The mixture was recrystallized twice from ethyl 
acetate and triturated with isooctane to give a 98 : 2 mixture of 
4a and 4b. Further recrystallization (2 x from ethyl acetate) 
gave pure 4a. HCl, m.p. 184-185°C; [I& -5.2” (c 0.34, 
CHCl3). Attempts to prepare alternate salts through the free 
base resulted in varying degrees of polymerization with resul- 
tant oiling out of the material. Although improved overall 
yields of the product could be obtained by initial deprotection 
as the hydrobromide, the resultant salt proved to be less 
amenable to isomeric purification through recrystallization. In 
addition, the hydrobromide salt was considerably less water 
soluble. 
2.7. Assignment of configuration of 4a and 4b 
The absolute configuration at C-2 was assigned spec- 
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Fig. 1. Structures of compounds and reaction sequence. 
troscopically by analogy to etoxadrol (3). Examination of 
nuclear magnetic resonance spectra show the C-4 proton of 
etoxadrol to be deshielded relative to the corresponding C-4 
resonance for its C-2 epimer epietoxadrol (3.79 vs 4.03 ppm). 
A similar effect was seen for 4a in relation to its C-2 epimer 4b 
(4.30 vs 4.42 ppm). In addition, similar isomeric ratios and 
relative CC retention times for 4a/4b and etoxadrol/epietox- 
adrol provide further indication that 4a and etoxadrol possess 
identical C-2 stereochemistry. 
2.8. 2R,4R,6R-2-(3-Zsothiocyanatophenyl)-2-ethyl-4-(2- 
piperidyl)-1,3-dioxolane) 
The dextrorotatory 2R,4R,6R_enantiomer of 4a was prepared 
from 2R,3R-2-piperidyl-l,2-ethanediol by the same series of 
reactions which gave 4a. Spectroscopic data (infrared and 
nuclear magnetic resonance) for the intermediate products 
leading to the dextrorotatory 2R,4R,6R_enantiomer of 4a were 
analogous to those obtained in the epimeric series. The 
hydrochloride salt of the dextrorotatory 2R,4R,6R_enantiomer 
of 4a was recrystallized from tetrahydrofuran, m.p. 
184-185”C, [& +4.2” (c 0.64, CHCl3). 
2.9. Binding assays 
Competitive binding experiments were performed as 
previously described [17] except that a tissue homogenate 
preparation of fresh whole rat brain minus cerebellum was 
used. Incubation was carried out at 5°C with [3H]TCP as the 
radioligand. Rapid filtration was carried out through filters 
presoaked in 0.03% polylysine. Experiments were performed in 
triplicate, and 10pM TCP was used for the determination of 
nonspecific binding. 
Irreversible binding experiments were performed using fresh 
tissue homogenates. The homogenates were incubated with 4a 
or the dextrorotatory 2R,4R,6R_enantiomer of 4a for 30 mitt at 
5°C and extensively washed to remove unreacted material. This 
wash procedure was found to be sufficient to remove a 10 ,uM 
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concentration of etoxadrol and a 50rM concentration of the 
dextrorotatory 2R,4R,6R_enantiomer of 4a, without loss of 
binding. Data from these experiments were analyzed using 
GraphPAD software [18]. Binding methodologies for ben- 
zodiazepine, muscarinic, and mu opioid receptors were taken 
from the literature [19-211. 
3. RESULTS 
Examination of the results of the displacement 
of [3H]TCP from untreated control tissue and 
tissue pretreated with 1 ,uM 2S,4S,6S-etoxadrol- 
meta-isothiocyanate (4a) revealed a loss of about 
50% of the total binding capacity in the treated 
tissue. Complete acylation could be obtained at a 
20 PM concentration. A Scatchard plot of the data 
(fig.2) shows that the loss of binding sites occurs 
without changing the relative affinity of the re- 
maining sites (& for control, 19.2 X 10T9 M; Kd 
for treated, 21.7 x 10e9 M; B,,, for control, 
1.36 pmol/mg protein; Bmax for treated, 
0.66 pmol/mg protein). The ligand displays an ap- 
parent ICSO of 590 nM. In contrast, the dex- 
trorotatory 2R,4R,6R_enantiomer of 4a showed an 
apparent IGo of 5 1 pM and, up to a 50 PM con- 
0- 
0 500 1000 1500 
Bound Ifmole/mg protein) 
Fig.2. Scatchard plots of [‘H]TCP binding in the presence (A) 
or absence (0) of 1 pM 2S,4S,6S-etoxadrol-meta-isothio- 
cyanate. 
Table 1 
Ability of 1 PM 2S,4S,6S-etoxadrol-meta-isothiocyanate (4a) to 
reversibly and irreversibly antagonize binding of various 
receptor ligands 
Ligand Maximum ICso GM) ICso 01M) 
% acylation for 4a for TCP 
by 1rM 
of 4a 
[‘H]TCPa 50 0.17 0.02 
[‘H]QNBb 0 3.6 40.3 
[3H]Flunitrazepam 0 >lOO >lOO 
[3H]FOXYC 0 18 2.0 
a ‘H-1-(1-(2-Thienyl]cyclohexyl)piperidine 
b ‘H-3-Quinuclidinyl benzilate 
’ 3H-3,14-Dihydroxy-4,5-epoxy-&B-fluoro-l7-methylmor- 
centration, did not irreversibly interact with the 
PCP site under conditions known to be effective 
for acylation by the active enantiomer 4a. An ex- 
amination of the time requirements for acylation 
by 4a revealed that less than 5 min was required to 
acylate all of the available sites, using a 1 PM con- 
centration. Longer exposure time (to 60 min) 
showed no appreciable change in total irreversible 
binding. The stability of 2S,4S,6S-etoxadrol-meta- 
isothiocyanate (4a) in aqueous solution was ex- 
amined by gas chromatographic analysis and 
ultraviolet spectroscopy. No detectable decom- 
position of etoxadrol-me&-isothiocyanate hydro- 
chloride could be observed after 24 h which was 
typical of aromatic isothiocyanates, which are 
known to react slowly with hydroxyl groups and 
much more rapidly with amines or thiol moieties. 
phinan 
The ligand concentrations used were: 1.8 nM [‘H]TCP, 
0.65 nM [‘HIQNB, 0.87 nM [3H]flunitrazepam and 1.6 nM 
[‘HIFOXY. The binding methodology for TCP was modified 
from 1171, using a tissue homogenate preparation of fresh 
whole rat brain minus cerebellum, and the others were from the 
literature [19-211. Acylation by 2S,4S,69etoxadrol+neta- 
isothiocyanate refers to the % acylation in washed, treated 
tissue compared with similarly washed controls. ICso values for 
2S,4S,6S-etoxadrol-meta-isothiocyanate were estimated from 
2S,4S,6S-Etoxadrol-meta-isothiocyanate (4a) 
showed no affinity for the benzodiazepine or 
muscarinic receptor systems in competitive binding 
experiments using [3H]flunitrazepam and [3H]- 
QNB, respectively, as the competitive ligands. 
Etoxadrol-meta-isothiocyanate was found to 
weakly displace [3H]FOXY from mu opioid recep- 
tors (I& = 25 FM) but did not irreversibly inac- 
tivate these receptors. 
4. DISCUSSION 
competitive displacement curves 2S,4S,6S-Etoxadrol-meta-isothiocyanate 
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an in vitro pharmacological profile similar to 
metaphit in that it will irreversibly bind to 
[3H]TCP sites in brain tissues and is specific for 
these sites. However, it is more potent than 
metaphit in its affinity to the PCP-binding site (ap- 
parent Ki of 590 nM and 2800 nM, respectively). 
Both the reversible and irreversible binding of 
etoxadrol-meta-isothiocyanate to the PCP-binding 
site are enantioselective; the 2S,4S,6S-etoxadrol- 
meta-isothiocyanate is the first example of an 
enantioselective lectrophilic affinity ligand for the 
PCP site. 
Recently, a report by Domino et al. [22] casts 
doubt on the use of metaphit as a valid affinity 
ligand for the PCP-binding site. They noted that 
the in vivo (intracerebroventricular administration 
in mice) actions of phenylisothiocyanate, an 
organic isothiocyanate which should be in- 
discriminate in its acylation of amines or thiol- 
containing amino acids, were similar to those 
found with metaphit (i.e., there were similar acute 
and delayed effects). While the enantioselective 
acylating properties of 2S,4S,6S-etoxadrol-meta- 
isothiocyanate do not conclusively contradict the 
in vivo work with metaphit by Domino et al., the 
enantioselectivity which we have found lends 
credence to the idea that the PCP site is not 
available for irreversible binding, at least in vitro, 
by reasonable concentrations of a potentially com- 
peting ligand possessing a similar acylating func- 
tionality. It is, of course, conceivable that 
introduction of a sufficiently large concentration 
of any electrophilic acylation agent will 
nonspecifically interact with all proteins contain- 
ing thiols or amino functions, in vivo or in vitro. 
The fact that a wide variety of structural classes 
has been shown to interact with the PCP-binding 
site has both facilitated and complicated the study 
of the binding site. In particular, the diversity of 
structures has made the identification of structural 
determinants for binding more complicated. The 
availability of new affinity ligands, like 2S,4S,6S- 
etoxadrol-meta-isothiocyanate, structurally based 
on different PCP agonist structural classes should 
aid in this area and thus, indirectly, in the elucida- 
tion of the nature of the binding site surface. 
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